Home›Cabozantinib

Cabozantinib

Also known as: Cometriq, Cabometyx

Route: Oral

28 interactions on record

Cabozantinib has 28 known drug interactions based on U.S. FDA drug labeling data. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Atazanavir, Clarithromycin, Indinavir. Patients taking Cabozantinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 28
Major: 10
Moderate: 18

Major (10)

Cabozantinib + Atazanavir— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Clarithromycin— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Indinavir— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Itraconazole— Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib La…
Cabozantinib + Ketoconazole— ( 2.2 , 7.2 ) 7.1 Effect of CYP3A4 Inhibitors Administration of a strong CYP3A4 inhibitor, ketoconazole to healthy subje…
Cabozantinib + Nelfinavir— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Ritonavir— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Saquinavir— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Telithromycin— Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazod…
Cabozantinib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…

Moderate (18)

Cabozantinib + Abacavir— Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudin…
Cabozantinib + Adefovir— Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudin…
Cabozantinib + Carbamazepine— Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.
Cabozantinib + Cidofovir— Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudin…
Cabozantinib + Furosemide— Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudin…
Cabozantinib + Grapefruit Juice— Grapefruit juice may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coa…
Cabozantinib + Grapefruit Products— Grapefruit may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadminis…
Cabozantinib + Lamivudine Oral— MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.
Cabozantinib + Nefazodone— Strong CYP3A4 inhibitor. Avoid concomitant use or reduce COMETRIQ dosage if unavoidable.
Cabozantinib + Nevirapine— MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.
Cabozantinib + Phenobarbital— Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.
Cabozantinib + Phenytoin— Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.
Cabozantinib + Probenecid— MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.
Cabozantinib + Rifabutin— Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.
Cabozantinib + Rifampin— Strong CYP3A4 inducer that decreased cabozantinib exposure by 77%. Avoid chronic co-administration or increase COMETRIQ …
Cabozantinib + Rifapentine— Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.
Cabozantinib + St. John'S Wort— St. John's wort may decrease exposure of cabozantinib, reducing efficacy. Avoid coadministration or increase CABOMETYX d…
Cabozantinib + Tenofovir— Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudin…

Cabozantinib + Atazanavir⚠️Major

Cabozantinib + Clarithromycin⚠️Major

Cabozantinib + Indinavir⚠️Major

Cabozantinib + Itraconazole⚠️Major

Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-emtansine Vinca alkaloids Avoid use during and 2 weeks after itraconazole treatment.

Cabozantinib + Ketoconazole⚠️Major

( 2.2 , 7.2 ) 7.1 Effect of CYP3A4 Inhibitors Administration of a strong CYP3A4 inhibitor, ketoconazole to healthy subjects increased single-dose plasma cabozantinib exposure by 38%. Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] .

Cabozantinib + Nelfinavir⚠️Major

Cabozantinib + Ritonavir⚠️Major

Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] . Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )] .

Cabozantinib + Saquinavir⚠️Major

Cabozantinib + Telithromycin⚠️Major

Cabozantinib + Voriconazole⚠️Major

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.

Cabozantinib + Abacavir🟡Moderate

Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )] .

Cabozantinib + Adefovir🟡Moderate

Cabozantinib + Carbamazepine🟡Moderate

Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.

Cabozantinib + Cidofovir🟡Moderate

Cabozantinib + Furosemide🟡Moderate

Cabozantinib + Grapefruit Juice🟡Moderate

Grapefruit juice may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.

Cabozantinib + Grapefruit Products🟡Moderate

Grapefruit may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.

Cabozantinib + Lamivudine Oral🟡Moderate

MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.

Cabozantinib + Nefazodone🟡Moderate

Strong CYP3A4 inhibitor. Avoid concomitant use or reduce COMETRIQ dosage if unavoidable.

Cabozantinib + Nevirapine🟡Moderate

MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.

Cabozantinib + Phenobarbital🟡Moderate

Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.

Cabozantinib + Phenytoin🟡Moderate

Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.

Cabozantinib + Probenecid🟡Moderate

MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.

Cabozantinib + Rifabutin🟡Moderate

Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.

Cabozantinib + Rifampin🟡Moderate

Strong CYP3A4 inducer that decreased cabozantinib exposure by 77%. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.

Cabozantinib + Rifapentine🟡Moderate

Strong CYP3A4 inducer. Avoid chronic co-administration or increase COMETRIQ dosage if unavoidable.

Cabozantinib + St. John'S Wort🟡Moderate

St. John's wort may decrease exposure of cabozantinib, reducing efficacy. Avoid coadministration or increase CABOMETYX dosage if unavoidable.

Cabozantinib + Tenofovir🟡Moderate

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.